Pharmacogenomics and CRISPR-based therapies

Area of Science:

• Genetics
• Pharmacology
• Biotechnology

Background:

• Pharmacogenomics analyzes genetic variations to tailor drug efficacy and minimize adverse reactions.
• CRISPR-Cas systems offer precise genome editing capabilities for targeted genetic alterations.

Purpose of the Study:

• To explore the synergistic relationship between CRISPR-based treatments and pharmacogenomics.
• To highlight applications in pharmacoresistance, cancer, and monogenic diseases.
• To address ethical, legal, and technical considerations for safe implementation.

Main Methods:

• Review of theoretical and practical frameworks linking CRISPR and pharmacogenomics.
• Analysis of recent applications in various disease contexts.
• Examination of ethical, legal, and technical challenges.

Main Results:

• CRISPR technology enhances pharmacogenomics by enabling gene expression modification and mutation correction.
• The combination facilitates personalized and potentially curative drug development.
• Applications show promise in treating pharmacoresistant conditions, cancers, and monogenic disorders.

Conclusions:

• The integration of CRISPR and pharmacogenomics represents a significant leap in precision medicine.
• This synergy paves the way for individualized therapies and novel treatment strategies.
• Addressing associated challenges is crucial for equitable and effective deployment.